日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inherent fast inactivation particle of Nav channels as a new binding site for a neurotoxin.

Nav通道固有的快速失活颗粒可作为神经毒素的新结合位点

Zhou Xi, Chen Haiyi, Peng Shuijiao, Si Yuxin, Wang Gaoang, Yang Li, Zhou Qing, Lu Minjuan, Xie Qiaoling, He Xi, Wu Meijing, Xiao Xin, Luo Xiaoqing, Feng Xujun, Wang Wenxing, Luo Sen, Li Yaqi, Qin Jiaxin, Chen Minzhi, Zhang Qianqian, Hu Weijun, Liang Songping, Hou Tingjun, Liu Zhonghua

Chlorophyll a/b-binding protein gene AcLhcb1.1 promotes chlorophyll accumulation and improves cold stress resistance in kiwifruit

叶绿素a/b结合蛋白基因AcLhcb1.1促进猕猴桃叶绿素积累并提高其抗寒性

Liu, Xinling; Zhang, Yingying; Ye, Daolin; Luo, Xiaoyan; Wu, Meijing; Zhang, Xiaoli; Xie, Yue; Liang, Dong; Xia, Hui

Triglyceride-glucose index and its related factors may be predictors for cardiovascular disease among Chinese postmenopausal women: a 12-year cohort study

甘油三酯-葡萄糖指数及其相关因素可能是中国绝经后女性心血管疾病的预测因子:一项为期12年的队列研究

Tu, Weiyan; Xu, Rongdi; Wang, Dan; Luo, Na; Wu, Meijing; Zhou, Yong; Ning, Jing

Discovery of Novel Na(v)1.7-Selective Inhibitors with the 1H-Indole-3-Propionamide Scaffold for Effective Pain Relief.

发现具有 1H-吲哚-3-丙酰胺骨架的新型 Na(v)1.7 选择性抑制剂,可有效缓解疼痛

Wang Gaoang, Wu Hang, Wang Yingying, Liu Xiangying, Peng Shuijiao, Wang Wenxing, Wu Meijing, Liu Yifei, Wang Ercheng, Wang Zhe, Xu Lei, Wang Xiaojian, Yang Wei, Chen Haiyi, Zhou Xi, Hou Tingjun

Optimizing Nav1.7-Targeted Analgesics: Revealing Off-Target Effects of Spider Venom-Derived Peptide Toxins and Engineering Strategies for Improvement

优化靶向 Nav1.7 的镇痛药:揭示蜘蛛毒液衍生肽毒素的脱靶效应及改进策略

Luo, Sen; Zhou, Xi; Wu, Meijing; Wang, Gongxin; Wang, Li; Feng, Xujun; Wu, Hang; Luo, Ren; Lu, Minjuan; Ju, Junxian; Wang, Wenxing; Yuan, Lei; Luo, Xiaoqing; Peng, Dezheng; Yang, Li; Zhang, Qingfeng; Chen, Minzhi; Liang, Songping; Dong, Xiuming; Hao, Guoliang; Zhang, Yunxiao; Liu, Zhonghua

Improving the Segmentation Accuracy of Ovarian-Tumor Ultrasound Images Using Image Inpainting

利用图像修复技术提高卵巢肿瘤超声图像分割精度

Chen, Lijiang; Qiao, Changkun; Wu, Meijing; Cai, Linghan; Yin, Cong; Yang, Mukun; Sang, Xiubo; Bai, Wenpei

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial

维利帕尼、紫杉醇给药方案和生殖系 BRCA 状态对浆液性卵巢癌一线治疗的影响——VELIA 试验的辅助数据分析

Aghajanian, Carol; Swisher, Elizabeth M; Okamoto, Aikou; Steffensen, Karina Dahl; Bookman, Michael A; Fleming, Gini F; Friedlander, Michael; Moore, Kathleen N; Tewari, Krishnansu S; O'Malley, David M; Chan, John K; Ratajczak, Christine; Hashiba, Hideyuki; Wu, Meijing; Dinh, Minh H; Coleman, Robert L

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

对于接受卡铂/紫杉醇治疗后进展的 gBRCA 晚期乳腺癌患者,铂类药物治疗间隔和 BRCA 基因逆转突变与 Veliparib 单药治疗的相关性(BROCADE3 交叉研究)

Puhalla, Shannon L; Diéras, Véronique; Arun, Banu K; Kaufman, Bella; Wildiers, Hans; Han, Hyo S; Ayoub, Jean-Pierre; Stearns, Vered; Yuan, Yuan; Helsten, Teresa; Riley-Gillis, Bridget; Murphy, Erin; Kundu, Madan G; Wu, Meijing; Maag, David; Ratajczak, Christine K; Ramathal, Cyril Y; Friedlander, Michael

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

维利帕尼联合卡铂/紫杉醇治疗HER2阴性转移性或局部晚期乳腺癌患者的安全性和有效性:基于BRCA1/2种系突变和激素受体状态的3期BROCADE3试验亚组分析

Ayoub, Jean-Pierre; Wildiers, Hans; Friedlander, Michael; Arun, Banu K; Han, Hyo S; Puhalla, Shannon; Shparyk, Yaroslav; Jakobsen, Erik H; Wu, Meijing; Bach, Bruce A; Feng, Dai; Ratajczak, Christine K; Maag, David; Diéras, Véronique

Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets

利用TCGA、GTEx和GEO数据集对卵巢癌淋巴细胞浸润相关lncRNA进行综合分析

Wu, Meijing; Shang, Xiaobin; Sun, Yue; Wu, Jing; Liu, Guoyan